Akero Therapeutics (NASDAQ:AKRO) is a clinical-stage biotechnology company focused on developing novel therapies for severe metabolic diseases, with an initial emphasis on nonalcoholic steatohepatitis (NASH). The company’s research platform leverages engineered versions of endocrine hormones to target key pathways involved in lipid metabolism, glucose regulation and tissue fibrosis. By harnessing the biology of fibroblast growth factor 21 (FGF21), Akero aims to address underlying drivers of metabolic dysfunction rather than merely treating symptoms.
The company’s lead product candidate, efruxifermin, is an Fc-FGF21 fusion protein designed to improve liver health and metabolic parameters in patients with NASH. Efruxifermin has demonstrated reductions in liver fat content, improvements in markers of liver injury and favorable changes in lipid and glucose profiles in early-phase clinical studies. Akero is advancing efruxifermin through pivotal trials, including global Phase 2 and Phase 3 studies, with the goal of achieving regulatory approval for patients with advanced liver fibrosis due to NASH.
Founded in 2017 and headquartered in Boston, Massachusetts, Akero Therapeutics operates research and development facilities in North America while engaging clinical sites across the United States and Europe. The company’s scientific leadership comprises experts in metabolic disease biology, protein engineering and drug development, supported by advisory collaborations with leading academic institutions. Akero’s board includes seasoned biotech investors and executives who guide its strategic direction.
In addition to its lead program, Akero is exploring preclinical candidates that modulate other hormone pathways implicated in cardiometabolic and fibrotic disorders. Through partnerships with contract research organizations and regulatory agencies, the company aims to expand its pipeline and ultimately deliver new treatment options for patients suffering from metabolic and liver diseases worldwide.
